Rule 17 disclosure

Summary by AI ^BETAClose X

EDX Medical Group plc has issued a Rule 17 disclosure regarding its non-executive chairman, Jason Christopher Holt, who resigned as a director of European Cargo Limited (ECL) on September 5, 2025. ECL subsequently entered administration on June 3, 2026, though EDX Medical states there is no business relationship between the two entities.

Disclaimer*

EDX Medical Group PLC

04 June 2026

A blue hexagon with white x and blue x Description automatically generated with low confidence

June 4, 2026

EDX Medical Group plc

("EDX Medical" or the "Company")

Rule 17 disclosure

CAMBRIDGE, UK: EDX Medical (TIDM: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer and infectious diseases, provides the following update pursuant to Rule 17 and Schedule 2g of the AIM Rules.

Jason Christopher Holt, non-executive chairman of EDX Medical, was a director of European Cargo Limited (ECL) and resigned that directorship on September 5, 2025. ECL subsequently entered into administration on June 3, 2026. There is no business relationship between EDX Medical and ECL.

ENDS

For enquiries, please contact:

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	+44 (0)7812 345 301
Canaccord Genuity Limited (Nominated Adviser and Broker)
Stuart Andrews	+44 (0) 20 7523 8318
Media House International
Ramsay Smith Gary McQueen	+44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk
IFC Advisory (Investor Relations)
Graham Herring Tim Metcalfe	+44 (0) 203 934 6630

About EDX Medical Group plc

The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END